-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, ErXW0h/hl9j9ruupiKbbjiqpmPMbMefs2et7i/6cI1wDSvrXCs5ZmJH84Y7Xk9sd /hOBF36DFoYmqllzmuekUw== 0000950162-03-001237.txt : 20030911 0000950162-03-001237.hdr.sgml : 20030911 20030911145752 ACCESSION NUMBER: 0000950162-03-001237 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20030911 ITEM INFORMATION: Other events ITEM INFORMATION: Financial statements and exhibits FILED AS OF DATE: 20030911 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SHIRE PHARMACEUTICALS GROUP PLC CENTRAL INDEX KEY: 0000936402 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-29630 FILM NUMBER: 03891821 BUSINESS ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 BUSINESS PHONE: 1264333455 MAIL ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 8-K 1 shire8k091103.txt FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2003 Shire Pharmaceuticals Group plc ________________________________________________________________________________ (Exact name of registrant as specified in its charter) England and Wales ________________________________________________________________________________ (State or other jurisdiction of incorporation) 0-29630 98-0359573 (Commission File Number) (IRS Employer Identification No.) Hampshire International Business Park, Chineham, Basingstoke, Hampshire RG24 8EP England ________________________________________________________________________________ (Address of principal executive offices) (Zip code) Registrant's telephone number, including area code 44 1256 894 000 ________________________________________________________________________________ (Former name or former address, if changed since last report) Item 5. Other Events Shire Pharmaceuticals Group plc has issued the press release attached as Exhibit 99.1 and incorporated by reference herein. Item 7. Financial Statements and Exhibits (c) Exhibits. The following exhibit is filed herewith: 99.1 Press Release dated September 11, 2003 -2- SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 11, 2003 SHIRE PHARMACEUTICALS GROUP PLC By: /s/ A C Russell ------------------------------- Name: Angus Russell Title: Group Finance Director EXHIBIT INDEX Number Description 99.1 Press Release dated September 11, 2003 EX-99.1 3 shire091103.txt PRESS RELEASE Shire Pharmaceuticals Group plc Hampshire International Business Park, Chineham, Basingstoke RG24 8EP UK Tel +44 1256 894000 Fax +44 1256 894708 http://www.shire.com Shire 11 September 2003 Shire Pharmaceuticals Group plc (the "Company") Application has been made to the UK Listing Authority and the London Stock Exchange for a block listing of 250,000 ordinary shares of 5p each to be admitted to the Official List. These shares, ranking pari passu in all respects with the existing shares in issue, will be allotted pursuant to the rules of the Shire Pharmaceuticals Group plc 2000 Executive Share Option Scheme (Part B). T May Company Secretary For further information please contact: Global (outside US and Canada) Clea Rosenfeld - Investor Relations +44 1256 894 160 US & Canada Gordon Ngan - Investor Relations +44 1256 894 160 Notes to editors Shire Pharmaceuticals Group plc Shire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently has a range of projects and products in the areas of central nervous system (CNS), gastrointestinal (GI), and renal. Shire has operations in the world's key pharmaceutical markets (US, Canada, UK, France, Italy, Spain and Germany) as well as a specialist drug delivery unit in the US. For further information on Shire, please visit the Company's website: www.shire.com -----END PRIVACY-ENHANCED MESSAGE-----